A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (CIMAX)
A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
Sponsor: Parexel
Listed as NCT02354105, this observational or N/A phase trial focuses on Axial Spondyloarthritis and remains completed. Sponsored by Parexel, it has been updated 13 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Apr 2019 — Jan 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Jun 2018 — Apr 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Status: Active Not Recruiting → Completed · Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
Apr 2017 — May 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Parexel
- UCB Biopharma S.P.R.L.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altenburg, Germany , Athens, Greece , Barcelona, Spain , Barnsley, United Kingdom , Basingstoke, United Kingdom , Bath, United Kingdom , Bayreuth, Germany , Berlin, Germany , Bilbao, Spain , Bolton, United Kingdom and 74 more locations